CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a. | June 5, 2023
Chrysalis Investments Ltd - London-headquartered trust investing in technology and finance startups - Notes Starling Bank revenue more than doubled in the year ended March 31 to GBP453 million from. | May 25, 2023
Chrysalis Investments Ltd - investor in technology and finance startups - Makes follow-on investment of GBP12.5 million into Smart Pension. Says the investment forms part of a USD95 million Series E. | May 15, 2023
Chrysalis Investments Ltd - investor in technology and finance startups - Net asset value as at March 31 is 130.03 pence per share, up 1.4% from 128.26 pence per share on December 31. Says positive. | May 4, 2023